Detail akcie CG Oncology Rg online

Business Summary: CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, CG Oncology Inc revenues increased from $683K to $1.7M. Net loss increased from $56.2M to $119.7M. Revenues reflect Biotechnology & Medical Research segment increase from $43K to $1.7M, United States segment increase from $43K to $1.7M. Higher net loss reflects Biotechnology & Medical Research segment loss increase from $28.3M to $142.1M, United States segment loss increase from $28.3M to $142.1M.